JP2022541523A5 - - Google Patents

Info

Publication number
JP2022541523A5
JP2022541523A5 JP2022502958A JP2022502958A JP2022541523A5 JP 2022541523 A5 JP2022541523 A5 JP 2022541523A5 JP 2022502958 A JP2022502958 A JP 2022502958A JP 2022502958 A JP2022502958 A JP 2022502958A JP 2022541523 A5 JP2022541523 A5 JP 2022541523A5
Authority
JP
Japan
Prior art keywords
cells
cancer
pharmaceutical composition
cell population
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541523A (ja
Filing date
Publication date
Priority claimed from GBGB1910605.3A external-priority patent/GB201910605D0/en
Application filed filed Critical
Publication of JP2022541523A publication Critical patent/JP2022541523A/ja
Publication of JP2022541523A5 publication Critical patent/JP2022541523A5/ja
Pending legal-status Critical Current

Links

JP2022502958A 2019-07-24 2020-07-24 腫瘍内浸潤リンパ球療法及びその用途 Pending JP2022541523A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962878001P 2019-07-24 2019-07-24
US62/878,001 2019-07-24
GBGB1910605.3A GB201910605D0 (en) 2019-07-24 2019-07-24 Tumour infltracting lymphocyte therapy amd uses thereo
GB1910605.3 2019-07-24
PCT/GB2020/051790 WO2021014174A1 (en) 2019-07-24 2020-07-24 Tumour infiltrating lymphocyte therapy and uses thereof

Publications (2)

Publication Number Publication Date
JP2022541523A JP2022541523A (ja) 2022-09-26
JP2022541523A5 true JP2022541523A5 (cg-RX-API-DMAC7.html) 2023-07-26

Family

ID=67839864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502958A Pending JP2022541523A (ja) 2019-07-24 2020-07-24 腫瘍内浸潤リンパ球療法及びその用途

Country Status (18)

Country Link
US (1) US20220378826A1 (cg-RX-API-DMAC7.html)
EP (1) EP4003372A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541523A (cg-RX-API-DMAC7.html)
KR (1) KR20220041839A (cg-RX-API-DMAC7.html)
CN (1) CN114174495A (cg-RX-API-DMAC7.html)
AU (1) AU2020316708A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001139A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142913A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000152A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021018066A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220027A (cg-RX-API-DMAC7.html)
EC (1) ECSP22004616A (cg-RX-API-DMAC7.html)
GB (1) GB201910605D0 (cg-RX-API-DMAC7.html)
IL (1) IL289235A (cg-RX-API-DMAC7.html)
MX (1) MX2022000439A (cg-RX-API-DMAC7.html)
PE (1) PE20220258A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550146A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021014174A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ (ユーケイ) リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
KR20230159840A (ko) * 2021-03-23 2023-11-22 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 항원 반응성 t 세포 수용체
WO2022271881A1 (en) * 2021-06-24 2022-12-29 Instil Bio, Inc. Methods of isolating of tumor infiltrating lymphocytes and use thereof
CN119643843B (zh) * 2022-03-15 2025-08-12 上海君赛生物科技有限公司 肿瘤特异性免疫细胞标志物及其用途
JP2024012879A (ja) * 2022-07-19 2024-01-31 国立大学法人三重大学 腫瘍反応性t細胞の製造方法
CN116162653A (zh) * 2023-03-30 2023-05-26 湖北省农业科学院畜牧兽医研究所 靶向切除猪SlamF1基因编码区DNA的成对编辑位点、使用方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1867720A3 (en) * 1994-12-02 2008-01-09 Schering Corporation Purified genes encoding mammalian cell surface antigens; proteins and antibodies
WO2002062999A2 (en) * 2000-12-29 2002-08-15 Curagen Corporation Proteins and nucleic acids encoding same
EP2336167B1 (en) * 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
ES2749862T3 (es) * 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
CN106459991B (zh) * 2014-04-07 2021-03-05 洛孔法尔马有限公司 新型药剂及其用途
WO2017179015A1 (en) * 2016-04-15 2017-10-19 Glaxosmithkline Intellectual Property Development Limited Compositions for the treatment of cancer
AU2018301668A1 (en) * 2017-07-12 2019-12-19 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
GB201801067D0 (en) * 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
CN113899903B (zh) * 2020-07-06 2025-08-29 上海市免疫学研究所 结直肠癌生物标志物及其在诊断、预防、治疗及预后中的应用
CN116769729B (zh) * 2023-06-05 2024-07-02 中国科学技术大学 靶向cd150的抗体或抗原结合片段及其应用

Similar Documents

Publication Publication Date Title
US11331385B2 (en) Methods of preparing anti-human papillomavirus antigen T cells
JP7653962B2 (ja) 濃縮された腫瘍反応性t細胞集団を腫瘍から作製する方法
KR101391395B1 (ko) 암환자의 면역치료를 위한 종양 반응성 t-림프구의개선된 증식방법
Martin et al. Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?
Wang et al. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment
Yang et al. The effect of metformin on senescence of T lymphocytes
CN111643524B (zh) 从外周血中产生肿瘤反应性t细胞富集群的方法
Baharlou et al. Reduced levels of T-helper 17-associated cytokines in the serum of patients with breast cancer: indicators for following the course of disease
KR20230150833A (ko) 세포 배양 방법
Zhang et al. RETRACTED ARTICLE: JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination
Friedmann et al. Interdependence of sequential cytotoxic T lymphocyte and natural killer cell cytotoxicity against melanoma cells
CN109439627B (zh) 一种极化和扩增cd4+t细胞的方法及组合物及在治愈表达特异性抗原的肿瘤中的应用
Ye et al. Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC
Lin et al. CD215+ myeloid cells respond to interleukin 15 stimulation and promote tumor progression
Fang et al. Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes
Stroncek et al. Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting
Rezalotfi et al. Gastrospheres as a model of gastric cancer stem cells skew th17/treg balance toward antitumor th17 cells
Hermans et al. Spatiotemporal dynamics of adoptively transferred stem-like CD8+ T cells in the tumor microenvironment following vaccination
De Silva et al. 180P Photodynamic priming of pancreatic cancer: Enabling immunotherapy
Janssen Predicting clinical outcome in melanoma and breast cancer using blood and tumour-based immune biomarkers: a means to monitor anti-cancer immune responses
Boutet et al. Loss of the MLL3 tumor suppressor accelerates breast tumor onset via HIF1α-induced CCL2-mediated recruitment of CCR2+ regulatory T cells
HK40088479B (en) Methods of preparing anti-human papillomavirus antigen t cells
HK40088479A (en) Methods of preparing anti-human papillomavirus antigen t cells
El Tayebi et al. 179P Paracrine crosstalk between LncRNA DILC and TNF-α release in tumor microenvironment of triple negative breast cancer
Da Costa et al. 177P TP53 and PRBM1 mutations predict “hot” tumor microenvironment in intrahepatic cholangiocarcinoima